Physician profile
Kenneth Lightheart
NPI 1740290360
$1,436.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $74.69 · 2021: $185 · 2022: $49.05 · 2023: $306 · 2024: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $328.31 | 2019-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $158.00 | 2019-2024 | |
| Abbott Laboratories | $128.27 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $123.71 | 2020-2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $120.00 | 2023 | Arcalyst |
| Medtronic, INC. | $116.29 | 2023-2024 | Symplicity G3, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $114.24 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $90.52 | 2021-2024 | Vigilant X4 Crt-D, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $72.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.38 | 2019 | |
| Amarin Pharma, INC. | $34.11 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $30.43 | 2019 | |
| Pfizer INC. | $29.49 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $21.96 | 2023 | Definity |
| Regeneron Healthcare Solutions, INC. | $17.03 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lightheart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.